Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
GY.9NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
AY.7.1 (Delta)NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
AY.7.1 (Delta)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.254NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
B.1.1.254NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
AY.36.1 (Delta)NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
AY.36.1 (Delta)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.121NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-4751.81US
B.1.1.121NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-4388.79US
AA.5NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
AA.5NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
AS.2NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
AS.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.115NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-21367.3US
B.1.1.115NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
AY.127.1 (Delta)NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
AY.127.1 (Delta)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.88NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
B.1.1.88NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BM.6NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
BM.6NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.5.2.46NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
BA.5.2.46NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.5.7NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
BA.5.7NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
CU.1NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
CU.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
CA.2NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
CA.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.177.83NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
B.1.177.83NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.1.11NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
XBB.1.11NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BQ.1.1.68NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
BQ.1.1.68NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BF.7.26NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
BF.7.26NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BR.1.2NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
BR.1.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BQ.1.1.25NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
BQ.1.1.25NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XSNSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
XSNSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
FL.4.7NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
FL.4.7NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.1.5.29NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
XBB.1.5.29NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.38NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
B.38NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.5.2.40NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used